Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HFNT vs. COT in COVID-19 (COVID-HIGH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04655638
Recruitment Status : Recruiting
First Posted : December 7, 2020
Last Update Posted : June 3, 2021
Sponsor:
Collaborator:
Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele
Information provided by (Responsible Party):
Andrea Cortegiani, MD, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

Brief Summary:
The aim of this unblinded parallel-group randomized multicenter clinical trial is to compare the clinical effectiveness of high flow nasal therapy (HFNT) with conventional oxygen therapy (COT) in patients with confirmed COVID-19 related acute hypoxemic respiratory failure.

Condition or disease Intervention/treatment Phase
Covid19 Acute Respiratory Failure Device: High Flow Nasal Therapy Device: Conventional Oxygen Therapy Not Applicable

Detailed Description:

The interventions will be delivered in any hospital ward caring for COVID-19 patients.

The interventions under investigation will be high flow nasal therapy in comparison with conventional oxygen therapy.

HFNT will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%. A feeding tube or a nasogastric tube will not represent a contraindication for the use of HFNT provided the patency of the used nostril.

Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.

Co-interventions: Patients potentially eligible for the study will be evaluated by the attending physicians and receive medical therapy based on the attending physician's decision and local protocols. Awake proning is allowed. Local protocols, including drugs and awake proning, will be discussed with the enrolling centers at the initiation visit, and adherence to WHO guidelines will be recommended. Written informed consent from all the patients will be collected.

Termination criteria & protocol violation: Criteria for weaning off COT or HFNT was at clinical discretion of the managing physician based on the improvement in oxygenation with ability to maintain SpO2 of 96% or greater with less than 0.30 of FiO2 or P/F > 300. The switch from COT to HFNT should be considered a protocol violation and should be based on clinical decision of the treating physician.

Criteria to be considered for escalation of treatment: 1) SpO2 ≤ 92% despite COT or HFNT or P/F ≤ 180 with FiO2 ≥ 50%, and 2) at least one of the following: respiratory rate ≥ 28 breaths/min, severe dyspnea, signs of increased work of breathing (e.g. use of accessory muscles). If the patient meets these criteria, escalation of treatment CPAP, NIV or IMV will be considered.

The choice of the type of escalating treatment will be a clinical decision of the treating physician.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 364 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Unblinded parallel-group randomized multicenter clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High-Flow Nasal Therapy Versus Conventional Oxygen Therapy in Patients With COVID-19: A Randomized Controlled Trial (The COVID-HIGH Trial)
Actual Study Start Date : February 10, 2021
Estimated Primary Completion Date : January 10, 2022
Estimated Study Completion Date : March 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Arm Intervention/treatment
Experimental: High Flow Nasal Therapy
High flow nasal therapy
Device: High Flow Nasal Therapy
High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.

Active Comparator: Conventional Oxygen Therapy
Conventional Oxygen therapy
Device: Conventional Oxygen Therapy
Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.




Primary Outcome Measures :
  1. Proportion of patients needing escalation of treatment during hospital stay [ Time Frame: 28 days ]
    Proportion of patients needing escalation of treatment (i.e. noninvasive ventilation - including CPAP - or intubation).


Secondary Outcome Measures :
  1. Proportion of patients needing intubation during hospital stay [ Time Frame: 28 days ]
  2. Proportion of patients who receive CPAP during hospital stay [ Time Frame: 28 days ]
    Proportion of patients who receive continuous positive airway pressure during hospital stay

  3. Proportion of patients who receive NIV during hospital stay [ Time Frame: 28 days ]
    Proportion of patients undergone noninvasive ventilation (e.g. BiLevel, PSV)

  4. Proportion of patients admitted to intensive care unit during hospital stay [ Time Frame: 28 days ]
  5. Proportion of patients who terminate the study protocols for improvement [ Time Frame: 28 days ]
  6. Length of stay in hospital [ Time Frame: 28 days ]
  7. Time to escalation of treatment to CPAP/NIV during hospital stay [ Time Frame: 28 days ]
  8. Time to escalation of treatment to intubation/invasive ventilation during hospital stay [ Time Frame: 28 days ]
  9. Length of stay in ICU [ Time Frame: 28 day ]
  10. Days free from CPAP/NIV during hospital stay [ Time Frame: 28 days ]
  11. Ventilator-free days during hospital stay [ Time Frame: 28 days ]
  12. Oxygen-free days during hospital stay [ Time Frame: 28 days ]
  13. 28-day mortality [ Time Frame: 28 days from hospital admission ]
  14. 60-day mortality [ Time Frame: 60 days from hospital admission ]
  15. Hospital mortality [ Time Frame: 28 days ]
  16. Treatment interruption due to intolerance during study treatment [ Time Frame: 28 days ]
  17. Dyspnea score (BORG scale) during hospital stay [ Time Frame: 28 days ]
    [0= no dyspnea to 10= severe dyspnea] - daily collection

  18. National Early Warning Score 2 (NEWS2) during hospital stay [ Time Frame: 28 days ]
    Daily collection of Six simple physiological parameters that form the basis of the scoring system: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, temperature. A score is allocated to each parameter, with the magnitude of the score reflecting how extremely the parameter varies from the norm. The score is then aggregated and uplifted by 2 points for people requiring supplemental oxygen to maintain their recommended oxygen saturation. Range of values: 0 (best) - 23 (worst) points.

  19. ROX index during hospital stay [ Time Frame: 28 days ]
    SpO2/FiO2/Respiratory rate - daily collection



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years old
  • Tested positive for SARS-CoV-2 using real-time reverse transcriptase PCR (RT-PCR) nasopharyngeal swabs
  • Clinical signs of acute respiratory infection and radiological evidence of pneumonia
  • Hospital admission in any ward or Emergency Department within 48 h
  • SpO2 ≤ 92% or PaO2/FiO2 < 300 in room air and need for oxygen therapy according to clinical judgment, at the screening.

Exclusion Criteria:

  • PaO2/FiO2 ≤ 200
  • Respiratory rate ≥ 28 breaths/min and or severe dyspnea and or use of accessory muscles
  • Need for immediate intubation or noninvasive ventilation (including CPAP) according to clinical judgment (e.g. clinical diagnosis of cardiogenic pulmonary edema, respiratory acidosis pH ≤ 7.3)
  • Patients already on CPAP/NIV or HFNT at study screening
  • Septic shock
  • Evidence of multiorgan failure
  • Glasgow Coma Scale < 13
  • Inability to comprehend the study content and give informed consent
  • PaCO2 > 45 mmHg, (if blood gas available) or history of chronic hypercapnia
  • Patient already on long-term oxygen therapy (LTOT) or home NIV/CPAP (even if only overnight)
  • Neuromuscular disease
  • Limitation of care based on patients' or physicians' decision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04655638


Contacts
Layout table for location contacts
Contact: Andrea Cortegiani, MD +390916552700 andrea.cortegiani@unipa.it
Contact: Claudia Crimi, MD dott.claudiacrimi@gmail.com

Locations
Show Show 24 study locations
Sponsors and Collaborators
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele
Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Andrea Cortegiani, MD, Principal Investigator, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
ClinicalTrials.gov Identifier: NCT04655638    
Other Study ID Numbers: 1th Dec 2020
First Posted: December 7, 2020    Key Record Dates
Last Update Posted: June 3, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Andrea Cortegiani, MD, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo:
COVID-19
HFNT
Respiratory failure
COT
Oxygen
Pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases